Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06369363
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-17
First Post:
2024-04-11
Brief Title:
Estrogen Deficiency on Cardiovascular Risk
Sponsor:
Milton S Hershey Medical Center
Organization:
Milton S Hershey Medical Center
Study Overview
Official Title:
Estrogen Deficiency on Cardiovascular Risk Sympathetic Responses and Pro-inflammatory Cytokines
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore how estrogen deficiency impacts the blood pressure BP and sympathetic nerve activity SNA and how it impacts the production of the key pro-inflammatory mediators such as Tumor necrosis factor α TNF-α interleukin-1β IL-1β and interleukin-6 IL-6 It is hypothesized that estrogen deficiency increases BP SNA and the pathway activities of the key pro-inflammatory mediators Those effects are impacted through the downregulation of the estrogen receptor
Detailed Description:
In the United States cardiovascular disease CVD is one of the major health concerns and affects approximately 65 million people over 40 As the number of elderly women increases CVD becomes an increasing problem Estrogen is cardioprotective and the menopause condition in the aging female population induces the loss of this protective effect There has been a dilemma for medical treatment in CVD patients with comorbidities including endometriosis or breast cancer history Overall these patients lose the cardioprotective effect of estrogen and increase the risk of CVD development However there is still little understanding regarding the mechanism for how estrogen suppression in women accelerates CVD development The proposed studies are therefore the essential first step to elucidating how estrogen alters mechanisms underlying CVD and provide the preclinical data to design studies for future alternative intervention strategies for CVD patients undergoing estrogen suppression therapies
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None